Phase I, Open-label, Single-center, Dose Escalation Study to Assess Safety and Tolerability of anti-CD19 CAR-T Cells in Patients with B-cell non-Hodgkin Lymphomas (CARMEN).

What you commit to

• Study type: Interventional · Phase 1
• Planned participants: 18
• 1 site in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with B-cell non-Hodgkin lymphoma, such as DLBCL or high grade B-cell lymphoma, to test the safety of anti-CD19 CAR-T cells.

Age

18 years or older

Sex

Women and men can join.

Disease stage

B-cell non-Hodgkin lymphoma, including DLBCL, aggressive B-cell lymphoma and high grade B-cell lymphoma with MYC and/or BCL2 and/or BCL6 rearrangement. The record gives no further stage details.

Read by machine on 9 Nov 2026.

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

Are you the coordinator? Confirm the details